Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TalpheraFRA:R5XA -1.77%35 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:R5XA with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Talphera ranks worse than 100% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Talphera's EBITDA for the
three
months ended in Mar. 2026 was €-3.42 Mil. Talphera's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Talphera's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Talphera (FRA:R5XA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Talphera EBITDA Margin % Related Terms
Talphera EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Talphera's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R5XA vs CTOR, ETST, INCR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Talphera EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Talphera's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Talphera's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talphera (FRA:R5XA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Talphera and its competitors. According to the industry distribution chart, Talphera ranks #959 out of 959 companies in the Drug Manufacturers industry.
Is Talphera's EBITDA Margin % too high?
Talphera's current EBITDA Margin % is 0.00%. Based on the distribution chart, Talphera ranks #959 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Talphera has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Talphera's EBITDA Margin % compare to CTOR and ETST?
According to the Drug Manufacturers industry distribution chart, Talphera ranks #959 out of 959 companies for EBITDA Margin %. This places Talphera in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Talphera and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Talphera's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talphera stock overvalued right now?
Talphera (FRA:R5XA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Talphera's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Talphera (FRA:R5XA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
35GF Score
Get the complete analysis for FRA:R5XA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R5XA has been successfully added to your 
